Fixed-dose combination tablet of SGLT2 inhibitor and DPP-4 inhibitor for type 2 diabetes. Obtained by endocrinology departments and chain pharmacies. Formulated by multinational pharma firms, supplied through regulated distribution to support comprehensive diabetes care programs.